PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer

NCT04539977 | Recruiting Phase 2

• 1 other identifier: LungMate-005(SCLC-TQB2450-001)
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This is a non-randomized, open-label, single-center, phase II trial to evaluate the safety and effectiveness of surgery or radiotherapy after PD-L1 inhibitor (TQB2450) and chemotherapy induction therapy followed by maintenance therapy as first-line treatment in patients limited-stage SCLC.

Conditions

Small-cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Objective response rate (ORR)

  It refers to the proportion of patients who have had a complete response or partial response (according to RECIST1.1) as confirmed by CT evaluation after 3 weeks in all patients who have completed the inductive/neoadjuvant therapy. Only patients with measurable lesions at baseline will be analyzed.

  up to 16 months

Secondary Outcomes (7)

• Event-free survival (EFS)

  up to 60 months

• Progression-free survival (PFS)

  up to 60 months

• Disease-free survival (DFS)

  up to 60 months

• Overall survival (OS)

  up to 63 months

• Major pathologic response (MPR)

  up to 5 months

Study Arms (2)

LS-SCLC Surgery

EXPERIMENTAL

Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles. Surgery (decided by MDT) Maintenance therapy: Etoposide,100 mg/m2 , d1-3 + Carboplatin,AUC5 (ivgtt, q3w,Two cycles) + TQB24501200mg, d1 (ivgtt, q3w, 1 Year) or progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen \[except radiotherapy\], withdrawal of informed consent or death).

Drug: TQB2450

LS-SCLC Radiotherapy

EXPERIMENTAL

Induction therapy: TQB2450 1200mg, d1+carboplatin (AUC5) , d1+ etoposide 100mg/m2, d1,d2,d3, q3w, 4 cycles. Radiotherapy (decided by MDT) Maintenance therapy: Etoposide,100 mg/m2 , d1-3+Carboplatin,AUC5 (ivgtt, q3w,Two cycles)+TQB24501200mg, d1(ivgtt, q3w, 1 Year) or progression disease, or other discontinuation criteria (intolerant toxicity, no more clinical benefit, receiving another anti-tumor regimen \[except radiotherapy\], withdrawal of informed consent or death).

Drug: TQB2450

Interventions

TQB2450 DRUG

Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)

Also known as: Carboplatin, Etoposide

LS-SCLC Surgery

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient shall sign the Informed Consent Form.
• Aged 18 ≥ years.
• Histological or cytological diagnosis of SCLC by needle biopsy, and extensive stage or limited stage (local advanced) confirmed by imageological examinations.
• Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1.
• Life expectancy is at least 12 weeks.
• At least 1 measurable lesion according to RECIST 1.1.
• Patients with good function of other main organs (liver, kidney, blood system, etc.):
• ANC count ≥1.5×10\^9/L, platelet count ≥100×10\^9/L，hemoglobin ≥90 g/L;
• the international standard ratio of prothrombin time (INR) and prothrombin time (PT) \< 1.5 times of upper limit of normal (ULN);
• partial thromboplastin time (APTT) ≤1.5×ULN;
• total bilirubin ≤1.5×ULN;
• alanine aminotransferase (ALT) aspartate aminotransferase (AST) ≤2.5×ULN, or ALT and AST ≤5×ULN in the patients with liver metastatic tumor.
• Fertile female patients must voluntarily use effective contraceptives not less than 120 days after chemotherapy or the last dose of TQB2450 (whichever is later) during the study period, and urine or serum pregnancy test results within 7 days prior to enrollment are negative.
• Unsterilized male patients must voluntarily use effective contraception during the study period not less than 120 days after chemotherapy or the last dose of TQB2450 (whichever is later).

You may not qualify if:

• Participants who have received any systemic anti-cancer treatment for SCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment;
• Administration of any Chinese medicine against cancer before administration of the drug;
• Participants with cancer other than SCLC (excluding cervical carcinoma in situ, cured basal cell carcinoma, bladder epithelial tumor \[including TA and tis\]) within five years before the start of this study;
• Participants with any unstable systemic disease (including active infection, uncontrolled hypertension), unstable angina pectoris, angina pectoris starting in the last three months, congestive heart failure (\>= NYHA) Grade II), myocardial infarction (6 months before admission), severe arrhythmia requiring drug treatment, liver, kidney or metabolic diseases;
• With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;
• Antibiotics were used to treat the infection for 4 weeks prior to the start of the trial;
• Participants who were systemically treated with corticosteroids (prednisone or other corticosteroids \>10 mg/ day) or other immunosuppressive agents within 2 weeks prior to first administration. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal hormone replacement therapy with a dose of less than 10 mg/ day of prednisone are permitted;
• Participants who are allergic to the test drug or any auxiliary materials
• Participants with active hepatitis B, hepatitis C or HIV;
• The vaccine was administered within 4 weeks of the start of the trial;
• Participants who have undergone major surgery or severe trauma in other systems within 2 months before the start of this trial;
• The patients have active pia meningioma, uncontrolled or untreated brain metastases.
• Pregnant or lactating women;
• Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
• Participated in another therapeutic clinical study

Sponsors & Collaborators

• Shanghai Pulmonary Hospital, Shanghai, China: lead

Study Sites (1)

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China

RECRUITING

MeSH Terms

Conditions

Small Cell Lung Carcinoma

Interventions

Carboplatin; Etoposide

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Podophyllotoxin; Tetrahydronaphthalenes; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Polycyclic Compounds; Glucosides; Glycosides; Carbohydrates

Central Study Contacts

Peng Zhang, MD

CONTACT

+8613512185932; zhangpeng1121@outlook.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of science and education department

Model Details: surgery or radiotherapy after PD-L1 inhibitor (TQB2450) and chemotherapy induction therapy followed by maintenance therapy in treating limited-stage small-cell lung cancer

Study Record Dates

• First Submitted: August 26, 2020
• First Posted: September 7, 2020
• Study Start: September 1, 2020
• Primary Completion: December 31, 2023
• Study Completion (Estimated): December 31, 2028
• Last Updated: May 9, 2023

Record last verified: 2023-05

Locations

CN (1)